Evidence map›Paper›PMID 27832126›Full record

Observational studyPloS one2016

Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.

Mark D Jesky, Mary Dutton, Indranil Dasgupta, Punit Yadav, Khai Ping Ng, Anthony Fenton, Derek Kyte, Charles J Ferro, Melanie Calvert, Paul Cockwell and 1 more

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Chronic kidney disease.Nature reviews. Disease primers · 2025
    Review
  16. Article
  17. Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mark D JeskyDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Mary DuttonDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Indranil DasguptaRenal Unit, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.
Punit YadavDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Khai Ping NgDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Anthony FentonDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Derek KyteInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Charles J FerroDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Melanie CalvertInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Paul CockwellDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Stephanie J StringerDepartment of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with reduced health-related quality of life (HRQL). However, the relationship between pre-dialysis CKD, HRQL and clinical outcomes, including mortality and progression to end-stage renal disease (ESRD) is unclear.

methodsAll 745 participants recruited into the Renal Impairment In Secondary Care study to end March 2014 were included. Demographic, clinical and laboratory data were collected at baseline including an assessment of HRQL using the Euroqol EQ-5D-3L. Health states were converted into an EQ-5Dindex score using a set of weighted preferences specific to the UK population. Multivariable Cox proportional hazards regression and competing risk analyses were undertaken to evaluate the association of HRQL with progression to ESRD or all-cause mortality. Regression analyses were then performed to identify variables associated with the significant HRQL components.

resultsMedian eGFR was 25.8 ml/min/1.73 m2 (IQR 19.6-33.7ml/min) and median ACR was 33 mg/mmol (IQR 6.6-130.3 mg/mmol). Five hundred and fifty five participants (75.7%) reported problems with one or more EQ-5D domains. When adjusted for age, gender, comorbidity, eGFR and ACR, both reported problems with self-care [hazard ratio 2.542, 95% confidence interval 1.222-5.286, p = 0.013] and reduced EQ-5Dindex score [hazard ratio 0.283, 95% confidence interval 0.099-0.810, p = 0.019] were significantly associated with an increase in all-cause mortality. Similar findings were observed for competing risk analyses. Reduced HRQL was not a risk factor for progression to ESRD in multivariable analyses.

conclusionsImpaired HRQL is common in the pre-dialysis CKD population. Reduced HRQL, as demonstrated by problems with self-care or a lower EQ-5Dindex score, is associated with a higher risk for death but not ESRD. Multiple factors influence these aspects of HRQL but renal function, as measured by eGFR and ACR, are not among them.

Indexed as

KidneyKidney Failure, ChronicQuality of LifeRenal Insufficiency, ChronicAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedProportional Hazards ModelsRenal DialysisRisk AssessmentRisk FactorsSelf Report

Identifiers

PMID27832126
PMCPMC5104414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.